New York State Common Retirement Fund Tcr2 Therapeutics Inc. Transaction History

New York State Common Retirement Fund

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$2.11 - $2.94 $28,470 - $39,669	-13,493 Reduced 98.04%	270 $1,000
Q4 2021 Feb 02, 2022	SELL	$4.58 - $8.34 $993 - $1,809	-217 Reduced 1.55%	13,763 $64,000
Q3 2021 Nov 02, 2021	SELL	$8.44 - $18.35 $116,024 - $252,257	-13,747 Reduced 49.58%	13,980 $119,000
Q2 2021 Aug 02, 2021	BUY	$16.41 - $24.71 $77,684 - $116,977	4,734 Added 20.59%	27,727 $455,000
Q4 2020 Feb 08, 2021	BUY	$19.0 - $32.63 $152,000 - $261,040	8,000 Added 53.36%	22,993 $711,000
Q2 2020 Aug 07, 2020	BUY	$6.51 - $16.85 $14,276 - $36,952	2,193 Added 17.13%	14,993 $230,000
Q4 2019 Feb 05, 2020	BUY	$12.17 - $17.88 $77,888 - $114,432	6,400 Added 100.0%	12,800 $183,000
Q3 2019 Nov 07, 2019	SELL	$10.15 - $19.53 $6,090 - $11,718	-600 Reduced 8.57%	6,400 $96,000
Q2 2019 Aug 09, 2019	BUY	$13.64 - $20.97 $95,480 - $146,790	7,000 New	7,000 $100,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.